<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

<sup>177</sup>Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer

The aim of this narrative review is to evaluate the current status of <sup>177</sup>Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant prostate cancer (mCRPC) in the light of the current literature. We also addressed patient preparation, therapy admi...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit: Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Materiálatiipa: Artihkal
Giella:English
Almmustuhtton: MDPI AG 2021-04-01
Ráidu:Biomedicines
Fáttát:
CRPC
<sup>177</sup>Lu-PSMA
PSA
prostate cancer
metastasis
Liŋkkat:https://www.mdpi.com/2227-9059/9/4/430

Interneahtta

https://www.mdpi.com/2227-9059/9/4/430

Geahča maid